



## **Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals**

**Cambridge, UK, 2 May 2019** – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, has been granted European patent EP3245226B1.

The patent covers methods for designing libraries for optimised immunoglobulins from transgenic animals.

**-Ends-**

**For more information, please contact:**

**Crescendo Biologics**

+ 44 (0)1223 497140

[info@crescendobiologics.com](mailto:info@crescendobiologics.com)

**Instinctif Partners**

Melanie Toyne-Sewell, Dr Christelle Kerouedan, Deborah Bell

+ 44 (0)20 7457 2020

[crescendo@instinctif.com](mailto:crescendo@instinctif.com)

**About Crescendo Biologics**

Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T-cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment – avoiding systemic toxicity.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V<sub>H</sub>). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com).